Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).
Intravenous preparations may leads to lower withdrawal due to adverse events compared with oral preparations (low certainty).
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).
5‐ASAs showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
5‐ASA may leads to lower withdrawal due to adverse events compared with purine antimetabolites (low certainty).
It is very uncertain whether 5‐ASAs changes withdrawal due to adverse events compared with anti TNF‐ɑ (very low certainty).
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
Tofacitinib probably leads to lower withdrawals due to adverse events (5 mg/10 mg) compared with placebo (moderate certainty).